Growth, pulmonary, and endocrine function in chronic asthma patients on daily and alternate-day adrenocorticosteroid therapy.
Growth, pulmonary, and adrenal-pituitary function were assessed in 20 steroid-dependent asthmatic children and adolescents while they were on daily prednisone therapy. The patients were then switched to equivalent daily methylprednisolone or twice equivalent alternate-day methylprednisolone for a 3-mo period, after which time studies were repeated. The steroid regimens were then crossed so that those patients taking daily methylprednisolone were switched to alternate-day therapy and the alternate-day therapy patients were switched to daily medication for another 3-mo interval, after which studies were repeated again. Abnormal growth, bone maturation, and cataracts were identified. Mean symptom scores at each evaluation were similar. Pulmonary function tests and shunt studies showed little difference between methylprednisolone and prednisone. Endocrine function tests showed a high incidence of disturbed pituitary and adrenal function. A 3-mo period of alternate-day therapy did not alter this.
D015065:17-Hydroxycorticosteroids / Q000097:blood / Q000652:urine; D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000328:Adult; D000365:Age Determination by Skeleton; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D001784:Blood Gas Analysis; D002648:Child; D002908:Chronic Disease; D005260:Female; D006128:Growth; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008797:Metyrapone / Q000494:pharmacology; D010913:Pituitary-Adrenal System / Q000503:physiopathology*; D011241:Prednisone / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D013997:Time Factors
D015065:17-Hydroxycorticosteroids; D000324:Adrenocorticotropic Hormone; D011241:Prednisone; D008775:Methylprednisolone; D008797:Metyrapone